

Stand: 16.01.2018

---

## 2018

### **Evidence for PTGER4, PSCA and MBOAT7 as risk genes for gastric cancer on the genome and transcriptome level.**

Heinrichs SKM, Hess T, Becker J, Hamann L, Vashist YK, Butterbach K, Schmidt T, Alakus H, Krasniuk I, Höblinger A, Lingohr P, Colette D, Ludwig M, Hagel AF, Schildberg CW, Veits L, Gyvyte U, Schüller V, Böhmer A, Schröder J, Gehlen J, Lordick F, Malfertheiner P, Möhler M, Pech O, Vassos N, Rodermann E, Izbicki JR, Kruschewski M, Ott K, Schumann RR, Vieth M, Mangold E, Kupcinkas L, Brenner H, Grimminger P, Bruns C, Gockel I, Nöthen MM, Lippert H, Ridwelski K, Lanas A, Keller G, Knapp M, Leja M, Kupcinkas J, Garcia-Gonzalez MA, Venerito M, Schumacher J

Carcinogenesis-Manuskript CARCIN-2017-00567; in preparation

### **Patient self reported WHO-ECOG-Score is frequently different to the assessment by oncologists.**

Losem C, Dombrowsky J, Schulte C, Koenigsmann M, Frank-Gleich S, Musch R, Steinmetz T, MVZ Onkologie/Hämatologie Neuss, Tumorzentrum Niederrhein, GP Hämatologie/Onkologie Dortmund, SP Onkologie/Hämatologie/Immunologie Hannover, GP Onkologie/Hämatologie/Gastroenterologie Halle/Saale, Praxis Onkologie/Hämatologie Berlin, GP Onkologie/Hämatologie Köln

Abstract DKK 2018 – 20170824.odt; in preparation

## 2017

### **Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.**

Dörfel S, Steffens CC, Meyer D, Tesch H, Kruggel L, Frank M, Jänicke M, Marschner N, the TMK-Group (Tumour Registry Breast Cancer)

Breast Cancer Res Treat. Springer, Dec 2017, doi.org/10.1007/s12282-017-0823-7

**Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study.**

Fietz T, Zahn MO, Köhler A, Engel E, Frank M, Kruggel L, Jänicke M, Marschner N, the TMK-Group (Tumour Registry Breast Cancer)

Breast Cancer Res Treat. Springer, Oct 2017 2017, doi.org/10.1007/s10549-017-4534-8

**Behandlung von Patienten mit metastasierten kolorektalen Karzinomen (mKRK) in 1° und 2°line nach vorheriger molekularer Markeranalyse mittels NGS unter realen Versorgungsbedingungen in onkologischen Schwerpunktpraxen- Zwischenergebnisse des GO-KOLORAS-Registers-.**

Lipp R, Freigang F, Eisen A, Brecht P, Tiemann M und die GO-KOLORAS Studiengruppe

Abstract P586. Jahrestagung DGHO Sept 30 – Oct 3 2017; Stuttgart

**Molekulare Markeranalysen von Patienten mit metastasierten kolorektalen Karzinomen (mKRK) und nachfolgenden Therapieentscheidungen in 1° und 2°line unter realen Versorgungsbedingungen in onkologischen Praxen.**

Lipp R, Freigang F, Eisen A, Brecht P, Tiemann M und die GO-KOLORAS-Studiengruppe

Abstract P585. Jahrestagung DGHO Sept 30 – Oct 3 2017, Stuttgart

**Molekulare Testung, molekulare Veränderungen und Erstlinienbehandlung von Patienten mit Nicht-kleinzelligem Lungenkrebs (NSCLC) in Deutschland. Erste Ergebnisse der Klinischen Register Plattform CRISP (AIO-TRK-0315)**

Griesinger F, Eberhardt WEE, Nusch A, Reiser M, Losem C, Ketzler-Henkel S, Zahn MO, Marschner N, Jaenicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, de Wit M, Metzenmacher M, Waller C, Kern J, Weichert W, Sebastian M, Thomas M

Abstract. Jahrestagung DGHO Sept 30 - Oct 3 2017, Stuttgart

**Myeloproliferative Neoplasien (MPN) in der Regelversorgung : Erste Daten aus dem NIHO-MPN-Register.**

Steinmetz HT, Heinz M, Lipke J, Sauer A, Fries S, Schneider-Kappus W, Uhlig J, Schmitz S

Abstract P549. Jahrestagung DGHO Sept 30 – Oct 3 2017, Stuttgart

**Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer: results from the MaTox project.**

Hurtz HJ, Tesch H, Göhler T, Hutzschenreuter U, Harde J, Kruggel L, Jänicke M, Marschner N, TMK-Group

Breast Cancer Res Treat. Springer, July 2017, doi: 10.1007/s10549-017-4365-7

**Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the prospective German TMK cohort study.**

Fietz T, Tesch H, Rauh J, Boller E, Kruggel L, Jänicke M, Marschner N, the TMK-Group (Tumour Registry Breast Cancer)

The Breast 2017; 34: 122-130

**Results of the 5th interim analysis of the non-interventional MOMENT II-study: efficacy and safety of Nilotinib in newly diagnosed Ph+CML patients in chronic phase.**

Tesch H, Lathan B, Sauer A, Tebbe S, Schulze M, Ulshöfer T, Lange E, Nusch A, Jäckle J, Janssen J, Rupprecht S, Meincke M, Tesanovic T

Abstract P538. Oncol Res Treat 2017; 40 (suppl3): 146

**Myelodysplastic syndrome (MDS) in regular care in Germany – the oldest patients come to the fore.**

Steinmetz HT, Germing U, Sauer A, Lathan B, Liersch R, Tesch H, Heßling J, Moorahrend E, Uhlig J, Reiser M, Wahdat R, Gattermann N, Totzke U, Schmitz S

Leukemia & Lymphoma 2017, <https://doi.org/10.1080/10428194.2017.1375105>

## **2016**

**Distribution of therapy regimen in patients with B-cell chronic lymphocytic leukemia (B-CLL) in 2015 in comparison to treatment strategies in 2012 based on real-world-evidence data of German oncological practices.**

Feuerbach M, Freigang F, Schulte C, Hurtz H-J, Schwarzer A, Lipp R

Abstract P861. Oncol Res Treat 2016; 39 (suppl3): 258

**A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC – a comparison of NGM and TCGA LUSC data.**

Koleczko S, Schäpers C, Scheffler M, Ihle M, Kostenko A, , Michels S, Fischer R, Nogova L, , Serke M, Kaminsky B, Benedikter J, Brümmendorf TH, Ficker JH, Lorenz J, , Schulte C, Schulze-Olden S, Brandes V, Abdulla D, Ueckerth F, Thurat M, Merkelbach-Bruse S, Büttner R, Wolf J

Abstract V134. Oncol Res Treat 2016; 39 (suppl3): 32

**Treatment results of 13 years CML therapy in a private office. A contribution of the German CML Alliance.**

Kämpfe D, Haverkamp T, Heil G, Schulte C, Tesch H, Stein H, Die Deutsche CML-Allianz

Abstract P215. Oncol Res Treat 2016; 39 (suppl3): 59

**Cost analysis of patients with relapsed or refractory multiple myeloma (MM) based on real-world-evidence data of German oncological practices.**

Feuerbach M, Freigang F, Schulte C, Hurtz H-J, Schwarzer A, Lipp R

Abstract P550. Oncol Res Treat 2016; 39 (suppl3): 164

**Analysis of potentially targetable mutations in 1056 patients with squamous cell lung cancer undergoing routine NGS-based molecular diagnostics.**

Koleczko S, Scheffler M, Steinhauser S, Kostenko A, Schäpers C, Michels S, Fischer R, Brandes V, Abdulla D, Nogova L, Ueckerth F, Thurat M, Serke M, Kaminsky B, Gerigk U, Benedikter J, Brümmendorf T, Ficker JH, Kruis W, Lorenz J, Schulte C, Schulze-Olden S, Merkelbach-Bruse S, Büttner R, Wolf J

Abstract P. 17th World Conference on Lung Cancer Dec 4-6 2016, Wien

**Prognosis of myelodysplastic syndrome (MDS) in patients in the age of 80 years and older: Data from the Regular Care MDS Registry in Germany.**

Steinmetz HT, Wahdat R, Haastert B, Sauer A, Lathan B, Lerchenmüller C, Tesch H, Germing U, Schmitz S

Blood 2016; 128:4333

Abstract P637. 58<sup>th</sup> Ann Meeting Am Soc Hem Dec 3-6 2016, San Diego, CA

Abstract P220. Jahrestagung DGHO Oct 14-16 2016, Leipzig

**Mutation profiling and consecutive treatment decisions under knowledge of mutation results in patients with metastatic colorectal cancer (mCRC) in real world evidence (RWE) of oncological practices – first results of the GO-KOLORAS registry study.**

Lipp R, Freigang F, Brecht P, Schwaner I, Steinmetz T, Schulte C, Tiemann M

Abstract P309. Oncol Res Treat 2016; 39 (suppl3): 97

Abstract: A-813-0024-00504. Jahrestagung der DGHO, OeGHO, SSMO, SSOM, SGMO und SGHSSH Oct 14-16 2016, Leipzig

**Efficacy and safety of Nilotinib in newly diagnosed Ph+ CML patients in chronic phase: Results of the 4<sup>th</sup> interim analysis of the non-interventional MOMENT II-study.**

Sauer A, Lathan B, Tebbe S, Ulshöfer T, Lange E, Schulze M, Nusch A, Janssen J, Losem C, Meincke M, Rupprecht S, Tesch H

Abstract P211. *Oncol Res Treat* 2016; 39 (suppl3): 52

Abstract P211. Jahrestagung DGHO Oct 14-16 2016, Leipzig

**Three years after the start of enrolment: Current data from the prospective chronic lymphocytic leukemia (CLL)-registry of the German CLL Study Group.**

Fink AM, Maurer C, Bahlo J, Kluth S, Linde H, Aldaoud A, Illmer T, Dengler J, Klausmann M, Lathan B, Al-Sawaf O, Fischer K, Wendtner CM, Eichhorst B, Hallek M

Abstract P855. *Oncol Res Treat* 2016; 39 (suppl3): 256

Abstract P. Jahrestagung DGHO Oct 14-16 2016, Leipzig

**The relevance of the international prognostic scoring system (IPSS) for patients with myelodysplasia (MDS) at higher age.**

Steinmetz HT, Wahdat R, Haastert B, Sauer A, Lathan B, Lerchenmüller C, Tesch H, Germing U, Schmitz S

Abstract P220. *Oncol Res Treat* 2016; 39 (suppl3): 61

Abstract P. Jahrestagung DGHO Oct 14-16 2016, Leipzig

**Clinical characteristics and long-term outcome of myeloid/lymphoid neoplasms with PDGFRB fusion genes in chronic or blast phase.**

Jawhar M, Naumann N, Schwaab J, Dietz C, Casper J, Dang TA, Dietze L, Döhner K, Hänel A, Lathan B, Link H, Lofti S, Lubert V, Maywald O, Müller L, Platzbecker U, Prümmer O, Thomssen H, Töpelt K, Schmitt K, Baurmann H, Vieler T, Hofmann WK, Haferlach C, Cross NCP, Fabarius A, Reiter A, Metzgeroth G

Abstract P. 21st Congress Eur Hem Ass June 9-12 2016, Copenhagen

**Age distribution of patients with myelodysplastic syndrome (MDS) in Germany and their prognosis according to the international prognostic scoring system (IPSS): Data from the regular care MDS registry.**

Steinmetz HT, Böttger I, Wahdat R, Haastert B, Sauer A, Lathan B, Germing U, Schmitz S

Abstract P. 21st Congress Eur Hem Ass June 9-12 2016, Copenhagen

**Mehr Eisen als uns gut tut – Expertenbericht: Bei der Hämochromatose ist eine unspezifische Leberwerterhöhung wichtig für die Differenzialdiagnose.**

Golka K, Collette D, Claus M, Niedner H, Butzeck B

Ärztewoche 28. April 2016, SpringerMedizin, Springer Verlag Heidelberg

**CONIFER – Non-interventional study to evaluate therapy monitoring during Deferasirox treatment of iron toxicity in MDS patients with transfusional iron overload in the course of treatment.**

Tesch H, Bruch HR, Dencausse Y, Heßling J, Lerchenmüller C, Michel G, Schlag R, Skorupa A, Schneider-Schranz C, Wolf S, Schulte C

DOI 10.1159/000447035

Oncol Res Treat 2016, 39 (7-8): 424-431

Abstract. 32. Deutscher Krebskongress Feb 24-27 2016, Berlin

**Efficacy and safety of Nilotinib in routine clinical management of newly diagnosed Ph+ CML patients in chronic phase – 3<sup>rd</sup> interim analysis of the non-interventional MOMENT II-study.**

Lathan B, Sauer A, Ulshöfer T, Lange E, Tebbe S, Schulze M, Janssen J, Meincke M, Frank O, Tesch H

Abstract P114. Deutscher Krebskongress Feb 24-27 2016, Berlin

**Hämochromatose – Wichtige Differentialdiagnose der unspezifischen Leberwerterhöhung. CME Zertifizierte Fortbildung.**

Golka K, Collette D, Claus M, Niedner H, Butzeck B

DOI 10.1007/s40664-016-0101-0

Zbl Arbeitsmed 2016/3; 66: 171-180

**Monitoring of deferasirox treatment in patients with transfusion-dependent iron toxicity due to myelodysplastic syndromes.**

Tesch H, Schulte C, Bruch HR, Dencausse Y

Poster. Centrum für Hämatologie und Onkologie Bethanien 2016, Frankfurt

## **2015**

**Ergebnisse einer Interimsanalyse der nicht-interventionellen MOMENT II-Studie zur Erfassung von Wirksamkeit und Sicherheit von Nilotinib bei neu diagnostizierten Ph+ CML-Patienten in chronischer Phase im klinischen Alltag.**

Lathan B, Sauer A, Ulshöfer T, Lange E, Tebbe S, Schulze M, Janssen J, Meincke M, Frank O, Tesch H

Abstract P456. Jahrestagung DGHO Oct 9-13 2015 Berlin

**Assessment of the myelodysplasia (MDS) international prognostic scoring system (IPSS) in routine care: Data from the regular care MDS registry.**

Steinmetz TH, Böttger I, Sauer A, Lathan B, Germing U, Schmitz S

Abstract V606. Jahrestagung DGHO Oct 9-13 2015 Berlin

## 2014

### **Interim Results of a Phase 2 Study of MEDI-551 and Bendamustine vs. Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia.**

Gladstone DE, André M, Zaucha JM, Assouline S, Bellam N, Cascavilla N, Jourdan E, Panwalkar A, Patti C, Schulte C, Zaja F, Goswami T, Elgeioushi N, Streicher K, Bao H, Spaner D

Abstract P4472. 56th Ann Meeting Am Soc Hem Dec 6-9 2014, San Francisco, CA

### **Phase 2 Open-Label Study of MEDI 551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL.**

Gladstone DE, André M, Zaucha JM, Araujo C, Assouline S, Bellam N, Cascavilla N, Jourdan E, Panwalkar A, Patti C, Schulte C, Zaja F, Goswami T, Elgeioushi N, Spaner D

Abstract 3028. J Clin Oncol 2014; 32 (suppl 5)

### **Results of an interim analysis of the non-interventional MOMENT II-study for determining efficacy and safety of Nilotinib in newly diagnosed Ph+ CML patients in chronic phase.**

Lathan B, Sauer A, Titgemeyer J, Groschek M, Gabrysiak T, Hutzenreuter U, Tebbe S, Meincke M, Frank O, Tesch H

Abstract P215. Oncol Res Treat 2014; 37 (suppl 5): 63

### **Hämochromatose – eine wichtige, selten gestellte Differentialdiagnose auch in der Arbeitsmedizin.**

Golka K, Collette D, Müller JF, Claus M, Niedner H, Butzeck B

Umweltmed – Hygiene – Arbeitsmed 19 (2) 2014

Abstract P. Betriebl. Gesundheitsförderung/2. 54. Wiss. Jahrestagung der DGAUM April 2-4 2014, Dresden

### **Need of transfusion, treatment and survival of patients with Myelodysplastic Syndromes (MDS): Update of the outpatient MDS registry.**

Steinmetz TH, Böttger I, Lathan B, Sauer A, Severin K, Germing U, Schmitz S

Abstract V. Jahrestagung DGHO Oct 10-14 2014 Hamburg

**2013**

**Efficacy and safety of Nilotinib in routine clinical management of newly diagnosed Ph+ CML patients in chronic phase – interim analysis of the non-interventional MOMENT II study.**

Lathan B, Sauer A, Titgemeyer J, Groschek M, Gabrysiak T, Hutzenreuter U, Tebbe S, Meincke M, Frank O, Tesch H

Abstract P217. Onkologie 2013; 36 (suppl 7): 62